Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 5/2013

01.09.2013 | Original Article

Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype

verfasst von: L. E. M. van den Berg, M. R. Drost, G. Schaart, J. de Laat, P. A. van Doorn, A. T. van der Ploeg, A. J. J. Reuser

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Pompe disease is a lysosomal storage disorder caused by acid α-glucosidase deficiency and characterized by progressive muscle weakness. Enzyme replacement therapy (ERT) has ameliorated patients’ perspectives, but reversal of skeletal muscle pathology remains a challenge. We studied pretreatment biopsies of 22 patients with different phenotypes to investigate to what extent fiber-type distribution and fiber-type-specific damage contribute to clinical diversity. Pompe patients have the same fiber-type distribution as healthy persons, but among nonclassic patients with the same GAA mutation (c.-32-13T>G), those with early onset of symptoms tend to have more type 2 muscle fibers than those with late-onset disease. Further, it seemed that the older, more severely affected classic infantile patients and the wheelchair-bound and ventilated nonclassic patients had a greater proportion of type 2x muscle fibers. However, as in other diseases, this may be caused by physical inactivity of those patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Bell RD, MacDougall JD, Billeter R, Howald H (1980) Muscle fiber types and morphometric analysis of skeletal msucle in six-year-old children. Med Sci Sports Exerc 12:28–31CrossRefPubMed Bell RD, MacDougall JD, Billeter R, Howald H (1980) Muscle fiber types and morphometric analysis of skeletal msucle in six-year-old children. Med Sci Sports Exerc 12:28–31CrossRefPubMed
Zurück zum Zitat Drost MR, Schaart G, van Dijk P et al (2008) Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 37:251–255CrossRefPubMed Drost MR, Schaart G, van Dijk P et al (2008) Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 37:251–255CrossRefPubMed
Zurück zum Zitat Fukuda T, Roberts A, Ahearn M, Zaal K, Ralston E, Plotz PH, Raben N (2006) Autophagy and lysosomes in Pompe disease. Autophagy 2:318–320CrossRefPubMed Fukuda T, Roberts A, Ahearn M, Zaal K, Ralston E, Plotz PH, Raben N (2006) Autophagy and lysosomes in Pompe disease. Autophagy 2:318–320CrossRefPubMed
Zurück zum Zitat Giesker D, Bowers GN Jr (1979) The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders. Conn Med 43:699–704PubMed Giesker D, Bowers GN Jr (1979) The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders. Conn Med 43:699–704PubMed
Zurück zum Zitat Gojo K, Abe S, Ide Y (2002) Characteristics of myofibres in the masseter muscle of mice during postnatal growth period. Anat Histol Embryol 31:105–112CrossRefPubMed Gojo K, Abe S, Ide Y (2002) Characteristics of myofibres in the masseter muscle of mice during postnatal growth period. Anat Histol Embryol 31:105–112CrossRefPubMed
Zurück zum Zitat Griffin JL (1984) Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 45:23–36CrossRefPubMed Griffin JL (1984) Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 45:23–36CrossRefPubMed
Zurück zum Zitat Grimby G, Aniansson A, Zetterberg C, Saltin B (1984) Is there a change in relative muscle fibre composition with age? Clin Physiol 4:189–194CrossRefPubMed Grimby G, Aniansson A, Zetterberg C, Saltin B (1984) Is there a change in relative muscle fibre composition with age? Clin Physiol 4:189–194CrossRefPubMed
Zurück zum Zitat Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ (2003) Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 1637:164–170CrossRefPubMed Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ (2003) Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 1637:164–170CrossRefPubMed
Zurück zum Zitat Hirschorn R, Reuser A (2001) Glycogen storage disease type II: acid alpha-glucosidase (Acid Maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle MD (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, pp 3389–3420 Hirschorn R, Reuser A (2001) Glycogen storage disease type II: acid alpha-glucosidase (Acid Maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle MD (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, pp 3389–3420
Zurück zum Zitat Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329–335CrossRefPubMedPubMedCentral Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329–335CrossRefPubMedPubMedCentral
Zurück zum Zitat Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109CrossRefPubMed Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109CrossRefPubMed
Zurück zum Zitat Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676CrossRefPubMed Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676CrossRefPubMed
Zurück zum Zitat Kriketos AD, Baur LA, O’Connor J, Carey D, King S, Caterson ID, Storlien LH (1997) Muscle fibre type composition in infant and adult populations and relationships with obesity. Int J Obes Relat Metab Disord 21:796–801CrossRefPubMed Kriketos AD, Baur LA, O’Connor J, Carey D, King S, Caterson ID, Storlien LH (1997) Muscle fibre type composition in infant and adult populations and relationships with obesity. Int J Obes Relat Metab Disord 21:796–801CrossRefPubMed
Zurück zum Zitat Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRefPubMed Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRefPubMed
Zurück zum Zitat Lexell J (1995) Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 50 Spec No: 11–16PubMed Lexell J (1995) Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 50 Spec No: 11–16PubMed
Zurück zum Zitat Lexell J, Taylor CC, Sjostrom M (1988) What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 84:275–294CrossRefPubMed Lexell J, Taylor CC, Sjostrom M (1988) What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 84:275–294CrossRefPubMed
Zurück zum Zitat Muller-Felber W, Horvath R, Gempel K et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17:698–706CrossRefPubMed Muller-Felber W, Horvath R, Gempel K et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17:698–706CrossRefPubMed
Zurück zum Zitat Raben N, Danon M, Gilbert AL et al (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80:159–169CrossRefPubMed Raben N, Danon M, Gilbert AL et al (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80:159–169CrossRefPubMed
Zurück zum Zitat Raben N, Fukuda T, Gilbert AL et al (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11:48–56CrossRefPubMed Raben N, Fukuda T, Gilbert AL et al (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11:48–56CrossRefPubMed
Zurück zum Zitat Raben N, Ralston E, Chien YH et al (2010) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 101:324–331CrossRefPubMedPubMedCentral Raben N, Ralston E, Chien YH et al (2010) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 101:324–331CrossRefPubMedPubMedCentral
Zurück zum Zitat Scelsi R, Marchetti C, Poggi P (1980) Histochemical and ultrastructural aspects of m. vastus lateralis in sedentary old people (age 65–89 years). Acta Neuropathol 51:99–105CrossRefPubMed Scelsi R, Marchetti C, Poggi P (1980) Histochemical and ultrastructural aspects of m. vastus lateralis in sedentary old people (age 65–89 years). Acta Neuropathol 51:99–105CrossRefPubMed
Zurück zum Zitat Schoser BG, Muller-Hocker J, Horvath R, Gempel K, Pongratz D, Lochmuller H, Muller-Felber W (2007) Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 33:544–559PubMed Schoser BG, Muller-Hocker J, Horvath R, Gempel K, Pongratz D, Lochmuller H, Muller-Felber W (2007) Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 33:544–559PubMed
Zurück zum Zitat Shea L, Raben N (2009) Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 47(Suppl 1):S42–S47PubMedPubMedCentral Shea L, Raben N (2009) Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 47(Suppl 1):S42–S47PubMedPubMedCentral
Zurück zum Zitat Straub V (2008) Diagnosis. In: Baethmann M, Straub V, Reuser AJJ (eds) Pompe disease. Bremen, UNI-MED, pp 51–54 Straub V (2008) Diagnosis. In: Baethmann M, Straub V, Reuser AJJ (eds) Pompe disease. Bremen, UNI-MED, pp 51–54
Zurück zum Zitat Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMed Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97CrossRefPubMed
Zurück zum Zitat Thurberg BL, Lynch Maloney C, Vaccaro C et al (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208–1220CrossRefPubMed Thurberg BL, Lynch Maloney C, Vaccaro C et al (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208–1220CrossRefPubMed
Zurück zum Zitat Turner DC, Eppenberger HM (1973) Developmental changes in creatine kinase and aldolase isoenzymes and their possible function in association with contractile elements. Enzyme 15:224–238PubMed Turner DC, Eppenberger HM (1973) Developmental changes in creatine kinase and aldolase isoenzymes and their possible function in association with contractile elements. Enzyme 15:224–238PubMed
Zurück zum Zitat van Capelle CI, Winkel LP, Hagemans ML et al (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447–452CrossRefPubMed van Capelle CI, Winkel LP, Hagemans ML et al (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447–452CrossRefPubMed
Zurück zum Zitat van den Berg LE, de Vries JM, Verdijk RM, van der Ploeg AT, Reuser AJ, van Doorn PA (2011) A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers. Neuromuscul Disord 21:232–234CrossRefPubMed van den Berg LE, de Vries JM, Verdijk RM, van der Ploeg AT, Reuser AJ, van Doorn PA (2011) A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers. Neuromuscul Disord 21:232–234CrossRefPubMed
Zurück zum Zitat van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340CrossRefPubMed van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340CrossRefPubMed
Zurück zum Zitat Van den Hout JM, Kamphoven JH, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457CrossRefPubMed Van den Hout JM, Kamphoven JH, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457CrossRefPubMed
Zurück zum Zitat van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMed van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406CrossRefPubMed
Zurück zum Zitat Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT (2005) The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884CrossRefPubMed Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT (2005) The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 252:875–884CrossRefPubMed
Zurück zum Zitat Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT (2003) Morphological changes in muscle tissue of patients with infantile Pompe’s disease receiving enzyme replacement therapy. Muscle Nerve 27:743–751CrossRefPubMed Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT (2003) Morphological changes in muscle tissue of patients with infantile Pompe’s disease receiving enzyme replacement therapy. Muscle Nerve 27:743–751CrossRefPubMed
Zurück zum Zitat Wokke JH, Escolar DM, Pestronk A et al (2008) Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 38:1236–1245CrossRefPubMed Wokke JH, Escolar DM, Pestronk A et al (2008) Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 38:1236–1245CrossRefPubMed
Metadaten
Titel
Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype
verfasst von
L. E. M. van den Berg
M. R. Drost
G. Schaart
J. de Laat
P. A. van Doorn
A. T. van der Ploeg
A. J. J. Reuser
Publikationsdatum
01.09.2013
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 5/2013
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9541-7

Weitere Artikel der Ausgabe 5/2013

Journal of Inherited Metabolic Disease 5/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.